Iovance Biotherapeutics (IOVA) Stock
Biotech developing cell therapies for solid tumors. Here's the price, business snapshot, and what's worth knowing about Iovance Biotherapeutics in October 2026.
Iovance Biotherapeutics, Inc. (IOVA) is a clinical-stage biotechnology company developing adoptive cell therapies based on tumour-infiltrating lymphocytes (TIL) for solid tumours. Its lead programme, lifileucel, targets cancers such as advanced melanoma and is being explored in other indications including cervical and non-small cell lung cancers. Investors should note Iovance is dependent on clinical trial readouts, regulatory milestones and the development of an industrial-scale manufacturing process for personalised cell therapies. With a market capitalisation of about $821m, the stock tends to exhibit biotech‑style volatility: positive trial or regulatory news can materially re-rate the share price, while setbacks or financing needs can depress it. This summary is educational and not personalised advice; prospective investors should assess their risk tolerance, research the company’s trial data and financial position, and consider seeking regulated financial advice before investing.
Iovance Biotherapeutics (IOVA) Stock Forecast
Analyst price target, next 12 months
$20.30
+38.9% vs today's $14.62
Price range over the last 12 months
Close to its 12-month high
Analysts covering Iovance Biotherapeutics have a consensus 12-month target of $20.30, above the current price of $14.62.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 11 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Iovance's stock, with a target price of $20.30 indicating growth potential.
Financial Health
IOVANCE is generating solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
TIL Immunotherapy Focus
Develops tumour‑infiltrating lymphocyte therapies, a personalised approach for solid tumours; manufacturing and regulatory hurdles remain, so outcomes can vary.
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory decisions could materially move the share price; these are binary events and can drive volatility.
Commercial Opportunity & Risk
If approved, therapies address sizeable oncology markets but require complex manufacturing, payer engagement and scalability — execution risk is significant.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
